- Home
- MRSN vs XLO Comparison
MRSN vs XLO Comparison
Compare MRSN & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- XLO
- Stock Information
- Founded
- MRSN 2001
- XLO 2016
- Country
- MRSN United States
- XLO United States
- Employees
- MRSN N/A
- XLO N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- MRSN Health Care
- XLO Health Care
- Exchange
- MRSN Nasdaq
- XLO Nasdaq
- Market Cap
- MRSN 47.1M
- XLO 40.9M
- IPO Year
- MRSN 2017
- XLO 2021
- Fundamental
- Price
- MRSN $9.76
- XLO $0.79
- Analyst Decision
- MRSN Strong Buy
- XLO Buy
- Analyst Count
- MRSN 3
- XLO 2
- Target Price
- MRSN $33.00
- XLO $3.00
- AVG Volume (30 Days)
- MRSN 69.2K
- XLO 475.7K
- Earning Date
- MRSN 11-12-2025
- XLO 11-07-2025
- Dividend Yield
- MRSN N/A
- XLO N/A
- EPS Growth
- MRSN N/A
- XLO N/A
- EPS
- MRSN N/A
- XLO N/A
- Revenue
- MRSN $34,769,000.00
- XLO $15,001,000.00
- Revenue This Year
- MRSN N/A
- XLO $519.70
- Revenue Next Year
- MRSN N/A
- XLO $44.57
- P/E Ratio
- MRSN N/A
- XLO N/A
- Revenue Growth
- MRSN 16.14
- XLO 536.45
- 52 Week Low
- MRSN $5.21
- XLO $0.62
- 52 Week High
- MRSN $70.75
- XLO $1.70
- Technical
- Relative Strength Index (RSI)
- MRSN 59.67
- XLO 53.98
- Support Level
- MRSN $8.76
- XLO $0.73
- Resistance Level
- MRSN $10.49
- XLO $0.85
- Average True Range (ATR)
- MRSN 0.84
- XLO 0.05
- MACD
- MRSN -0.06
- XLO -0.00
- Stochastic Oscillator
- MRSN 56.87
- XLO 43.25
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).